Abstract. Evodiamine is one of the major bioactive compounds isolated and purified from the fruit of Fructus Evodiae. Numerous studies have indicated that evodiamine exhibits activity against human tumor cells. In the present study, the effect of evodiamine on the proliferation and apoptosis of SGC-7901 human gastric cancer cells and the correlative mechanisms were investigated. This may provide further experimental evidence of the pharmacological actions of evodiamine and a strategy for its use as a novel chemotherapeutic drug. Following treatment with evodiamine, the typical morphological changes of apoptosis were observed in human SGC-7901 cells. Cell cycle analysis indicated that evodiamine induced G2/M phase arrest in SGC-7901 cells and flow cytometry revealed that evodiamine induced apoptosis. Analysis of the enzymatic activity demonstrated that evodiamine increased the activity of caspase-3, -8 and -9 in SGC-7901 cells. The protein expression of caspase-3, -8 and -9 and Bax increased, and the expression of Bcl-2 decreased following treatment with evodiamine. These results suggest that evodiamine is able to inhibit the proliferation of SGC-7901 cells by inhibiting the cell cycle at G2/M phase and inducing apoptosis in SGC-7901 cells by activating caspase-3, -8 and -9, and altering the expression of caspase
Introduction
Fructus Evodiae, a traditional Chinese medicine, has been used in the treatment of headache, abdominal pain, postpartum hemorrhage, dysentery and amenorrhea (1) . Evodiamine is the most important quinoline alkaloid isolated from the fruit of Fructus Evodiae. Evodiamine has been demonstrated to possess numerous biological effects, including analgesic, anti-inflammatory, antiobesity, vasodilatory, thermoregulatory and uterotonic effects (1) . In recent years, studies investigating the anticancer mechanisms of evodiamine have become a major topic of focus. Certain studies have suggested that evodiamine has anticancer activity by inducing apoptosis, arresting the cell cycle and inhibiting tumor invasion and metastasis. Evodiamine has been demonstrated to inhibit the proliferation of multiple tumor cells, including human leukemia (2) , malignant melanoma (3) (4) (5) , thyroid carcinoma (6) , prostate cancer (7-9), breast cancer (10), hepatoma (11, 12) , cervical cancer (5, 6, 13) , colon carcinoma (14, 15) and pancreatic cancer (16) cells.
Cancer is not only a disease exhibiting abnormal cellular proliferation and differentiation, but is also a disease with abnormal apoptosis. Previous studies on apoptosis and its mechanisms have provided a novel method for overcoming cancer, that is, the induction of apoptosis in tumor cells rather than the inhibition of tumor cell proliferation. Various methods may be used to induce apoptosis in tumor cells or to establish the optimal conditions for this induction.
Gastric carcinoma is one of the most common types of malignancy and is the leading cause of cancer-related mortality in China (17) . Chemotherapy is one of the main therapeutic approaches for treating gastric cancer. However, the effect of evodiamine on gastric carcinoma remains poorly defined and the exact mechanisms are unclear. Examining the molecular mechanisms underlying the effects of evodiamine on gastric carcinoma cells may provide novel methods for the treatment of gastric cancer and add to the growing evidence that evodiamine may be used as a systemic anticancer drug.
The SGC-7901 human gastric cancer cell line is an ideal cellular model to study the proliferation and differentiation of gastric cancer in vitro, which has the advantages of a simple in vitro amplification and rapid entry to the exponential phase. Consequently, the present study selected the SGC-7901 cell line for investigation.
Our previous study (18) demonstrated that evodiamine inhibits the proliferation and induces apoptosis of SGC-7901 gastric cancer cells, and the half effective inhibitory concentration (IC 50 ) of evodiamine is 1.5 µmol/l. In the present study, SGC-7901 cells were treated with 1.5 µmol/l evodiamine for different time periods and the effects on proliferation and apoptosis were observed. The present study investigates the possible molecular mechanisms by which evodiamine affects SGC-7901 cells. 
Growth inhibition and induction of apoptosis in

Results
Effect of evodiamine on cellular morphology. Following treatment with evodiamine, the morphological changes in the cells were observed by inverted microscopy. In the evodiamine groups, SGC-7901 cells became irregular and exhibited shrinkage. Detachment of the cells from the cell culture substratum was observed (Fig. 1) . These changes were characteristic of apoptotic cell death. In the control groups, cell morphology did not change significantly. Hoechst 33258 staining was used to detect chromatin condensation, one of the typical morphological features of apoptosis. The Hoechst 33258 dye stained morphologically normal nuclei dimly blue, whereas evodiamine-treated cells demonstrated smaller nuclei with brilliant blue staining (Fig. 2) . Compared with the control cells, the cells exposed to evodiamine presented typical apoptotic morphology. These results demonstrate that evodiamine induces the morphological changes of apoptotic cell death in SGC-7901 cells.
Effects of evodiamine on cell cycle progression. To investigate whether the antiproliferative effect of evodiamine was associated with cell cycle arrest, analysis of cell cycle phase distribution was performed following treatment with evodiamine using flow cytometry. Evodiamine treatment resulted in the accumulation of SGC-7901 cells at the G2/M phase (Fig. 3A) . Following treatment with evodiamine, the number of SGC-7901 cells that arrested at the G2/M phase was elevated by 34.4, 44.4 and 59.2% at 12, 24 and 36 h, respectively (Fig. 3B) . These results indicated that evodiamine was able to affect the distribution of the cell cycle and induce G2/M arrest in SGC-7901 cells.
Effects of evodiamine on caspase activity. To investigate the molecular mechanism of evodiamine-induced apoptosis, the activity of caspase-3, -8 and -9 in SGC-7901 cells was examined. The results demonstrated that the caspase-3 activity of SGC-7901 cells was markedly increased following treatment (Fig. 4A) . Evodiamine increased the activity of caspase-8 in SGC-7901 cells following exposure for 12, 24 and 36 h (Fig. 4B) . The activity of caspase-9 was elevated following treatment with evodiamine for 12, 24 and 36 h (Fig. 4C) .
Western blot analysis of caspase-3, Bax and Bcl-2 protein.
The treatment of SGC-7901 cells with 1.5 µmol/l evodiamine for 24 h resulted in an increase in caspase-3 expression (Fig. 5) . Bax expression was elevated following incubation with evodiamine for 24 and 36 h. The expression of Bcl-2 was increased following evodiamine treatment for 12 and 24 h and decreased following 36 h. The expression of β-actin served as an internal control. These data demonstrated that evodiamine induced the apoptosis of SGC-7901 cells through a caspase-dependent pathway.
Discussion
Apoptosis is an autonomic ordered, programmed, physiological mode of cell death that is important in tissue homeostasis and is controlled by serial genes. Cancer is not only a disease with abnormal cellular proliferation and differentiation but also a disease with abnormal apoptosis. Numerous types of tumors are the result of an imbalance between cell proliferation and cell death. Thus, investigating the basic mechanisms of apoptosis may provide insight into potential novel therapeutic targets and have vital significance. Evodiamine is one of the major bioactive compounds isolated and purified from the fruit Fructus Evodiae. Several studies (2,6-8,10) have indicated that evodiamine exhibits activity against human tumor cells. Our previous study (18) demonstrated that evodiamine inhibits the proliferation of SGC-7901 gastric cancer cells. In the present study, the molecular mechanisms by which evodiamine affects SGC-7901 cells were investigated and novel evidence was identified for the future medical use of evodiamine. The previous study determined whether evodiamine was toxic for normal peripheral blood mononuclear cells (PBMCs). The results demonstrated that evodiamine exhibited less toxicity in PBMCs that were treated with various concentrations of evodiamine for 24 h. From the early tests it was concluded that evodiamine-induced cell death was mediated by time-and dose-dependent pathways, and the optimal concentration and exposure time was 1.5 µm/l for 24 h. The present study also demonstrated that DMSO, as a co-solvent, exhibited no cytotoxic effect on SGC-7901 cells. Therefore, the IC 50 of evodiamine was selected to act upon SGC-7901 cells.
Morphological alteration is an important characteristic of apoptosis. Alterations, including cell shrinkage, cell detachment, chromatin condensation, nuclear fragmentation and formation of apoptotic bodies are characteristic of cell apoptotic death. Cellular morphological analysis demonstrated that SGC-7901 cells underwent typical apoptotic changes following treatment with evodiamine.
Evodiamine has been demonstrated to induce cell cycle arrest in prostate (7, 8) , breast (10) and colorectal cancer (14, 15) . Flow cytometry indicated that evodiamine induced cell cycle arrest at the G2/M phase in SGC-7901 cells. The cells in G2/M phase mainly synthesize RNA and protein, and prepare for cell division. The present study inferred that evodiamine may affect the synthesis of proteins that are essential for cells, thus inhibiting the proliferation of SGC-7901 cells.
In order to gain insight into the molecular mechanisms underlying the effects of evodiamine in apoptosis, the enzyme activity of caspase-3, -8 and -9 was determined. Numerous internal and external signal stimuli are able to induce apoptosis. Although there are various signals and pathways that follow, it is generally considered that the common pathway of late apoptosis is the activation of the caspase family. Caspases are the central executioners in the apoptotic process. Caspases are divided into two functional subfamilies, including promoter caspases (caspase-8 and -9) and effector caspases (caspase-3 and -7). The activated promoter caspase is able to activate effector caspases, thus completing apoptosis.
Data from the present study demonstrated that caspase-3, -8 and -9 were activated by evodiamine following incubation for 24 and 36 h, indicating that evodiamine resulted in apoptosis of SGC-7901 cells mediated by the activation of caspase-3, -8 and -9. Furthermore, western blotting demonstrated that the expression of caspase-3 also increased following evodiamine treatment for 24 and 36 h.
The Bcl-2 protein family and its members form a complicated interactive network, which is able to regulate apoptosis. Among these proteins, the expression of Bax and Bcl-2 is directly associated with apoptosis regulation. The increased expression of Bax and decreased expression of Bcl-2 is able to promote apoptosis. In the present study, data suggested that the expression of Bax was increased following evodiamine treatment for 24 and 36 h. Evodiamine increased Bcl-2 expression at 12 and 24 h and decreased Bcl-2 expression at 36 h. Bcl-2 is important in tumorigenesis by inhibiting the signals that induce apoptosis. Bcl-2 is also phosphorylated in vivo and this modification has been demonstrated to effect its anti-apoptotic activity (19) . In addition, Bcl-2 is able to inhibit or delay apoptosis induced by various stimuli, including chemotherapeutic drugs. As a result, the present study inferred that, in the early stages of evodiamine action, increased Bcl-2 expression may be a delayed action of cells on external stimulated factors, so as to prevent the cytotoxic effect of evodiamine and protect the cells. However, it was not able to prevent apoptosis and the rate of apoptosis at this stage was elevated. When drug treatment was prolonged to 36 h, the decreased Bcl-2 expression may have been associated with the stimulatory effect of evodiamine exceeding the cellular regulatory activity, which may have been responsible for the induction of apoptosis in SGC-7901 cells. The results indicate that the apoptosis caused by evodiamine in SGC-7901 cells may be associated with the alteration of the Bcl-2 protein family.
In conclusion, the results of the present study suggest that evodiamine inhibits the proliferation of SGC-7901 cells by arrest at the G2/M phase. In addition, evodiamine is able to activate caspase-3, -8 and -9, upregulate the expression of caspase-3 and Bax, and downregulate the expression of Bcl-2, potentially the mechanism by which evodiamine induces the apoptosis of SGC-7901 cells.
